Translational Drug Development

Provectus Biopharmaceuticals Launches Preclinical Study of Oral PV-10 for Bladder Cancer Treatment

- Provectus Biopharmaceuticals has initiated a preclinical study evaluating oral PV-10 in an orthotopic bladder cancer model, with results expected in Q1 2026. - The study will assess PV-10's performance across multiple treatment approaches including oral and intravesical monotherapy and combination with anti-PD-1 checkpoint inhibitors. - PV-10 is formulated from pharmaceutical-grade rose bengal sodium, a first-in-class synthetic small molecule from the halogenated xanthene family. - Successful results could expand PV-10's investigational new drug application and support broader immuno-oncology applications across solid tumor and hematologic cancers.